Monoclonal Antibody Combo Reduces Marburg Disease Risk

In COVID-19, Latest News by Precision Vaccinations

A recent study conducted at the Galveston National Laboratory at The University of Texas Medical Branch at Galveston (UTMB) has shown a significant benefit to combining monoclonal antibodies and the antiviral remdesivir (Veklury) against advanced Marburg virus.
Marburg hemorrhagic fever is a severe and highly fatal disease caused by a virus from the same family that causes Ebola, says the World Health Organization (WHO).

Read More